NCT03126110 2025-08-14Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Completed145 enrolled 47 charts
NCT03665285 2024-03-08A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid TumorsNextCure, Inc.Phase 1/2 Completed109 enrolled 25 charts
NCT03642990 2023-04-12NR in Chemo-induced Peripheral NeuropathyUniversity of IowaPhase 2 Terminated5 enrolled 11 charts
NCT03241173 2022-09-27A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Completed52 enrolled 25 charts
NCT02178722 2022-02-14Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersIncyte CorporationPhase 1/2 Completed444 enrolled 19 charts
NCT02001623 2021-12-29Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsSeagen Inc.Phase 1/2 Completed195 enrolled 51 charts
NCT03245736 2021-11-04Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.Seagen Inc.Phase 2 Completed5 enrolled 8 charts
NCT03006887 2021-05-20Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid TumorsEisai Inc.Phase 1 Completed6 enrolled 27 charts
NCT00538850 2014-03-05Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainINSYS Therapeutics IncPhase 3 Completed130 enrolled 9 charts